Ibuprofen lysinate and sodium ibuprofen for prophylaxis of patent ductus arteriosus in preterm neonates.

Abstract

This retrospective, study compared the efficacy and safety of Ibuprofen-Lysinate (Arfen, intramuscular formulation, Group I, n=156) used during 2000-2005 and Sodium-ibuprofen (Pedea, intravenous solution, Group II, n=60) used during 2006-2008, for the prophylaxis of Patent Ductus Arteriosus in inborn neonates with gestational age ≤ 28 weeks. Ductus closure rate after prophylaxis was significantly higher (73.1% vs 50%; P=0.002) and surgical ligation significantly lower (8.2% vs 23.3%; P=0.005) in Group I. A smaller number of neonates of Group I vs Group II showed oliguria and hemorrhagic disease.

• Authors: M P De Carolis, I Bersani, G De Rosa, F Cota, C Romagnoli
• Journal: Indian pediatrics (Indian Pediatr) Vol. 49 Issue 1 Pg. 47-9 (Jan 2012) ISSN: 0974-7559 [Electronic] India
• PMID: 21992864 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Cyclooxygenase Inhibitors
• Lysine
• solufenum
• Ibuprofen

Topics

• Cyclooxygenase Inhibitors (therapeutic use)
• Ductus Arteriosus, Patent (drug therapy)
• Humans
• Ibuprofen (administration & dosage, analogs & derivatives, therapeutic use)
• Infant, Newborn
• Infant, Premature, Diseases (drug therapy)
• Lysine (administration & dosage, analogs & derivatives, therapeutic use)
• Retrospective Studies
• Treatment Outcome